Page last updated: 2024-09-05

orantinib and Cancer of Ovary

orantinib has been researched along with Cancer of Ovary in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Caniatti, M; Cherrington, JM; Colombo, T; Garofalo, A; Ghilardi, C; Ghisleni, G; Giavazzi, R; Manenti, L; Naumova, E; Nicoletti, MI; Scanziani, E	1
Kohno, T; Konno, R; Machida, S; Mizuno, I; Ohwada, M; Saga, Y; Suzuki, M; Takayama, T; Takei, Y	1

Other Studies

2 other study(ies) available for orantinib and Cancer of Ovary

Article	Year
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-15, Volume: 9, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Oxindoles; Paclitaxel; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2	2003
Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). International journal of cancer, 2005, Mar-20, Volume: 114, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Metastasis; Ovarian Neoplasms; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Survival Analysis; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2005

Article

Year

The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-15, Volume: 9, Issue:9

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Oxindoles; Paclitaxel; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2

2003

Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).

International journal of cancer, 2005, Mar-20, Volume: 114, Issue:2

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Metastasis; Ovarian Neoplasms; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Survival Analysis; Transplantation, Heterologous; Vascular Endothelial Growth Factor A

2005